Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (464)	2/24/2005 8:50:37 PM
From: zeta1961	of 946

the fact that an inactive prodrug is largely excreted as an inactive prodrug simply suggests that this excreted fraction can not contribute to a therapeutic effect. In fact, this fully embraces the premise and theory behind conjugated drugs... :-) The above is a statement of the obvious..It seems to me that the more productive discussion would not be about Miljenko's past statements about Xyotax since he's not posting in response but to look at the recently published paper to see if it increases our knowledge about the PK/PD and and if it helps us understand the clinical data when it is reported or better yet to 'guesstimate' the data based on what we know now about the progress of the trials... No?? Zeta

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next